Platform Technologies – Capsids Solid continues to broaden access to its proprietary next-generation capsid, AAV-SLB101, designed with the goal of enhancing skeletal muscle and cardiac tropism with ...
A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD ...
A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in ...
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 ...
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer baseAdvance SeaStar Medical’s ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Objectives Left ventricular assist devices (LVADs) have become important treatments for end-stage heart failure; however, studies of post-LVAD life experiences are limited. The aim of this study was ...
CLINICAL QUESTION: Among patients with ischemic cardiomyopathy and ventricular tachycardia, is catheter ablation or antiarrhythmic drug therapy a more effective initial strategy BACKGROUND: ...
Objectives: Stroke is a severe complication in patients with left ventricular assist devices (LVAD), significantly affecting quality of life and potentially leading to death. This study aimed to ...
Madrid, Spain – 29 August 2025: Targeting high-normal potassium levels reduced the risk of arrhythmias, hospitalisation for heart failure or arrhythmia and death compared with no intervention, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback